AngioDynamics, Inc. (ANGO) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ANGO Revenue Growth
Revenue Breakdown (FY 2024)
ANGO's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
ANGO Revenue Analysis (2014–2025)
As of May 8, 2026, AngioDynamics, Inc. (ANGO) generated trailing twelve-month (TTM) revenue of $307.3 million, reflecting solid growth of +9.0% year-over-year. The most recent quarter (Q2 2026) recorded $79.4 million in revenue, up 4.9% sequentially.
Looking at the longer-term picture, ANGO's 5-year compound annual growth rate (CAGR) stands at +2.1%, indicating moderate growth over time. The company achieved its highest annual revenue of $359.5 million in 2019.
Revenue diversification analysis shows ANGO's business is primarily driven by Med Device (65%), and Med Tech (35%). With over half of revenue concentrated in Med Device, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NVCR (+8.5% YoY), ATRC (+15.0% YoY), and MMSI (+11.2% YoY), ANGO has underperformed the peer group in terms of revenue growth. Compare ANGO vs NVCR →
ANGO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ANGOCurrent | $307M | +9.0% | +2.1% | -13.7% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 ATRC | $535M | +15.0% | +20.9% | -0.6% | |
 MMSI | $1.5B | +11.2% | +9.5% | 12.2% | |
 ITGR | $1.8B | +6.0% | +11.5% | 11.3% | |
 CNMD | $1.4B | +4.4% | +9.8% | 10.3% |
ANGO Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $292.5M | -3.8% | $157.7M | 53.9% | $-39,954,000 | -13.7% |
| 2024 | $303.9M | -10.3% | $154.7M | 50.9% | $-192,435,000 | -63.3% |
| 2023 | $338.8M | +7.1% | $174.2M | 51.4% | $-51,181,000 | -15.1% |
| 2022 | $316.2M | +8.7% | $165.7M | 52.4% | $-28,471,000 | -9.0% |
| 2021 | $291.0M | +10.2% | $156.8M | 53.9% | $-35,283,000 | -12.1% |
| 2020 | $264.2M | -26.5% | $150.3M | 56.9% | $-167,098,000 | -63.3% |
| 2019 | $359.5M | +4.4% | $156.0M | 43.4% | $-9,396,000 | -2.6% |
| 2018 | $344.3M | -1.5% | $143.9M | 41.8% | $-14,170,000 | -4.1% |
| 2017 | $349.6M | -1.1% | $143.9M | 41.2% | $-11,175,000 | -3.2% |
| 2016 | $353.7M | -0.9% | $174.3M | 49.3% | $1.0M | 0.3% |
See ANGO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ANGO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ANGO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonANGO — Frequently Asked Questions
Quick answers to the most common questions about buying ANGO stock.
Is ANGO's revenue growth accelerating or slowing?
ANGO maintains +9.0% revenue growth, in line with its 5-year CAGR of +2.1%. TTM revenue stands at $307M. Growth rate remains consistent with historical average.
What is ANGO's long-term revenue growth rate?
AngioDynamics, Inc.'s 5-year revenue CAGR of +2.1% reflects the sustained expansion pattern. Current YoY growth of +9.0% is near this long-term average.
How is ANGO's revenue distributed by segment?
ANGO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.